Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Revolution's Rasonque Gets Broad Pancreatic Cancer Recommendation in Europe

15 October 2026 · By · Wire by Fusion42

Published

15 October 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at genomeweb.com →

◆ Verified

Fusion42 · 16 October 2026 · Fusion42 review

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of Revolution Medicines' Rasonque (daraxonrasib) in Europe for metastatic pancreatic adenocarcinoma patients regardless of RAS mutation status after prior systemic therapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.

◆ ◆ The Wire takeaway

You can now target metastatic pancreatic cancer patients without RAS mutation testing in Europe, opening access and speeding up patient enrolment or commercial efforts for your therapies.

◆ Coverage

48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026

◆ Related on Wire

◆ Topics

Biotechemadrug-approvalpancreatic-cancerrevolution-medicines